China's First Independently Developed Anti-Influenza Drug, Yisuda® (Masulavir), Launches Online via JD Health

On May 16, the domestically produced new anti-influenza drug Yisuda^®(Generic name: Marboxil Tablets) made its online debut on JD Health. This drug was independently developed by Jiangxi Kerui Pharmaceutical Co., Ltd., a subsidiary of Qingfeng Pharmaceutical. It is China’s first antiviral medication targeting the PA subunit of the influenza virus RNA polymerase, indicated for the treatment of influenza A and B in adolescents aged 12 years and older and adults. The entire course of treatment requires only a single dose. Users can purchase it by searching for “Yisuda” on the JD App.

As a respiratory infectious disease that poses a serious threat to public health, influenza impacts people’s work and daily lives every year. For a long time, China’s anti-influenza drug market has relied heavily on imported medications, often leading to shortages during peak flu seasons. Yisuda^®Its market launch fills the gap for domestically developed innovative drugs in this field, providing Chinese patients with a new treatment option.

It is reported that Yisuda^®It is the second drug globally and the first in China to be independently developed that targets the PA subunit of the influenza virus RNA polymerase. Its most notable feature is its ability to directly act on the viral core, rapidly blocking viral replication. Unlike traditional anti-influenza medications that require multiple doses, Yisuda® requires only a single dose throughout the entire course of treatment to quickly alleviate symptoms. Furthermore, this new drug has an overall resistance mutation rate of less than 1%, significantly lower than that of similar anti-influenza drugs, ensuring more stable therapeutic efficacy.

It is worth mentioning that Yisuda^®All clinical study data are derived from Chinese patient populations, making them more suitable for the physical constitutions of the Chinese population. Meanwhile, the localized production model ensures the stability of drug supply, providing a reliable safeguard for seasonal influenza prevention and control in China.

In recent years, JD Health has leveraged its robust supply chain capabilities to continuously consolidate its position as the premier platform for the nationwide online launch of new and specialty drugs. By providing mature solutions for the initial market introduction of new pharmaceuticals, JD Health accelerates omni-channel expansion and delivers treatment options to patients that are synchronized with global standards.

A representative from JD Health’s Pharmaceutical Business Division stated, “We are delighted to partner with Qingfeng Pharmaceutical to jointly promote Yisuda”^®online launch. JD Health will fully leverage its omnichannel advantages and healthcare service capabilities to help this milestone domestic innovative drug benefit more patients.”

In the future, JD Health will continue to collaborate with more global pharmaceutical partners to jointly improve the accessibility of new and specialty drugs, providing patients with more medication options.